https://www.selleckchem.com/pr....oducts/tofa-rmi14514
We identified higher mortality (3.25% vs 3.56%, p less then 0.001), length of stay (5.2 vs 6.1 days, p less then 0.001) and inflation-adjusted cost of stay (12,562 vs 13,072 USD, p less then 0.001) in HF hospitalizations with AECOPD when compared to HF without AECOPD from 2004 to 2014. We presented AECOPD as an independent predictor of mortality in patients admitted for HF. In conclusion, further interdisciplinary collaboration between pulmonologists and cardiologists is needed for the identification and stratification of patients
Like
Comment
Share